# A new approach in the treatment of ultrasound-guided synovial hypertrophy

**Authors:** Emel GÜLER, Alper DOĞANCI

PMC · DOI: 10.55730/1300-0144.5955 · Turkish Journal of Medical Sciences · 2024-11-11

## TL;DR

This study shows that injecting anesthetic and steroid into the knee joint and synovial tissue reduces pain and improves function in patients with severe knee osteoarthritis.

## Contribution

A novel injection method targeting synovial hypertrophy in knee OA is evaluated for long-term pain and function improvement.

## Key findings

- Pain and functional capacity improved significantly after the injection method.
- Synovial hypertrophy regressed as shown by ultrasound evaluations.
- Improvements were sustained for up to 12 months post-injection.

## Abstract

Knee osteoarthritis (OA) causes pain and limited movement, negatively impacting daily life in older adults. Hypertrophy and changes in the synovial tissue significantly contribute to the pain. While intraarticular injections are common in OA treatment, specific therapies for hypertrophic tissue are rarely mentioned. This study aimed to evaluate the long-term outcomes of local anesthetic and steroid injections in the knee’s intraarticular space and hypertrophic synovial tissue.

Our retrospective study included patients with grade 3 or 4 knee OA diagnosed with ultrasound-guided suprapatellar effusion and synovial hypertrophy. Pain was assessed using a numerical rating pain scale (NRS) and functional capacity was evaluated with the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index. Effusion was first drained from the suprapatellar region using a 22-gauge spinal needle under ultrasound guidance, followed by lavage with 40 mL of 0.9% NaCl solution. A mixture of 10 mL (2 mL triamcinolone hexacetonide, 7 mL of prilocaine, and 1 mL of 0.9% NaCl) was injected intraarticularly, and 6 mL was injected into the hypertrophic synovial tissue. Patients were followed before the injection and at 1, 3, 6, 9, and 12 months after the injection.

Analysis of the WOMAC scores and NRS values at 1, 3, 6, 9, and 12 months after the injection revealed statistically significant reductions (p < 0.05). No statistical difference was found between the duration of complaints and WOMAC scores or NRS values (p > 0.05). Ultrasound evaluation indicated regression of the synovial hypertrophy tissue.

This injection method, practiced in the treatment of synovial hypertrophy as one of the causes of pain in knee OA, reduced pain and significantly increased functional capacity.

## Linked entities

- **Chemicals:** triamcinolone hexacetonide (PubChem CID 21826), prilocaine (PubChem CID 4906), 0.9% NaCl (PubChem CID 5234)

## Full-text entities

- **Diseases:** hypertrophic (MESH:D002312), synovial hypertrophy (MESH:D013585), OA (MESH:D010003), Knee osteoarthritis (MESH:D020370), Effusion (MESH:D000080324), Pain (MESH:D010146)
- **Chemicals:** steroid (MESH:D013256), NaCl (MESH:D012965), triamcinolone hexacetonide (MESH:C005900), prilocaine (MESH:D011318)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11913489/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11913489/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC11913489/full.md

---
Source: https://tomesphere.com/paper/PMC11913489